Health Canada has approved Moderna’s COVID-19 vaccine for use in this country, with 168,000 doses expected to arrive by the end of the year.
The federal department announced the approval on Wednesday after completing a review of the Massachusetts-based biotechnology company’s clinical trial data.
“The data provided supports favourably the efficacy of the Moderna COVID-19 vaccine as well as its safety,” Health Canada said in a notice authorizing use of the vaccine for people over the age of 18.
“There were no important safety issues identified and no life-threatening adverse events (AEs) or deaths related to the vaccine.”
The authorization of a second COVID-19 vaccine comes as cases surge across the country.
Health Canada authorized a vaccine made by U.S. pharmaceutical giant Pfizer and German biotechnology firm BioNTech on Dec. 9, and that vaccine is already being administered in parts of the country to people in high-priority groups, including health-care workers and long-term care workers and residents.
Dr. Howard Njoo, Canada’s deputy chief public health officer, said 240,000 of those doses will have been distributed to all provinces by the end of the day — enough to vaccinate 120,000 Canadians.
Moderna vaccine easier to store
The Moderna approval means vaccinations can now begin in northern, remote and Indigenous communities, which haven’t seen any doses of the Pfizer-BioNTech vaccine because they lack the freezer equipment necessary to safely store it at –70 C.
Moderna’s vaccine, by contrast, can be stored at regular freezer temperatures.
“This authorization is a critical step in ensuring a COVID-19 vaccine is available to all Canadians in all parts of the country,” Dr. Supriya Sharma, Health Canada’s chief medical adviser, said at a press conference in Ottawa on Wednesday.
“Since many Canadians live outside major urban areas, this vaccine can be used in communities that haven’t had access to COVID-19-vaccines to date.”
Canada has secured an agreement to receive 40 million doses of the Moderna vaccine by the end of 2021 — enough to vaccinate 20 million Canadians.
Sharma said Canada would receive up to 168,000 doses of the Moderna vaccine before the end of December.
Danielle Marceau, a health worker at the CHSLD St-Antoine long-term care home, is injected with the Pfizer-BioNTech COVID-19 vaccine in Quebec City on Dec. 14. (Pat Lachance/Quebec Ministry of Health and Social Services via Reuters)
Prime Minister Justin Trudeau told a news conference on Wednesday that doses of the Moderna vaccine would start arriving “in the coming days.”
Trudeau also announced that Canada had secured an agreement for delivery of an additional 250,000 doses from Pfizer next month, bringing the total number of doses expected to be delivered by Pfizer in January to 751,000.
“Between the early doses we have already received and the shipments now scheduled, we’re on track to have at least 1.2 million doses from both Pfizer and Moderna delivered by Jan. 31,” Trudeau said.
Maj.-Gen. Dany Fortin, the military commander leading vaccination logistics at the national operations centre, said everything is in place for the rapid distribution of Moderna doses to designated sites in the provinces and territories, following a successful dry-run last week.
“We are ready to deliver up to 168,700 doses next week,” he said.
Fortin said the first vaccine doses will arrive in the territories on Dec. 28, unless weather becomes an issue. He also said the number of vaccine distribution sites in Canada would expand over the next few weeks, from 14 now to more than 100 next week.
The distribution plans for the two vaccines are different. Pfizer-BioNTech has chosen to ship doses directly to provincial sites using shipping company UPS, while the Public Health Agency of Canada is responsible for delivering doses of the Moderna vaccine.
PHAC has contracted FedEx to pick up doses in Europe and deliver them to a storage facility in Toronto, where logistics company Innomar will repackage the shipments into smaller amounts to be forwarded to provincial and territorial governments.
Patricia Gauthier, general manager of Moderna Canada, told CBC News that shipments, which will include all 168,000 doses, could start within 48 hours of approval.
What do you want to know about COVID vaccines, or anything related to the pandemic? Send us your questions and tips to COVID@cbc.ca and find answers to your questions on our website: cbc.ca/ask
Clinical trial results
Health Canada granted authorization to Moderna’s vaccine after analyzing data from a Phase 3 trial that involved over 30,000 individuals in the U.S., half of whom received the vaccine while the other half received a placebo.
The vaccine was found to be 94.1 per cent effective in participants with no prior COVID-19 infection and 86.5 per cent effective in people over the age of 65, Health Canada said.
Data showed the vaccine’s effectiveness and safety were consistent across age, sex and ethnicity.
During the trial, 30 people in the placebo group experienced severe cases of COVID-19, compared with none from the vaccine group, Health Canada said.
Health Canada warned that people shouldn’t take the vaccine if they are allergic to any of its ingredients, or if they currently have symptoms of COVID-19.
Moderna vaccine requires 2 doses
The vaccine is not yet recommended for use on children, as tests on adolescents only began in December and tests on children younger than 12 won’t begin until next year.
Health Canada said in a statement that Moderna will have to continue to provide information to the regulator on the safety of the vaccine.
Like the Pfizer-BioNTech vaccine, Moderna’s shot requires two doses to achieve maximum immunity.
It uses mRNA technology — a technology that directs cells to produce proteins that trigger an immune response to prevent or fight the virus that causes COVID-19.
The two doses should be taken one month apart.
Health Canada continues to review two other COVID-19 vaccines — one from U.K.-based pharmaceutical company AstraZeneca and another from Janssen Inc., a Canadian pharmaceutical subsidiary of Johnson & Johnson. Sharma said the regulator requires more data from both before it can make a decision.
Wednesday’s approval comes as concerns grow about the emergence in the U.K. of a new, more contagious variant of the coronavirus that causes COVID-19, which has led to concern that it may reduce the efficacy of existing vaccines.
Chief Public Health Officer Dr. Theresa Tam said on Tuesday that there is no evidence to suggest that existing vaccines won’t be effective against the new variant.